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ABSTRACT  
 
X-linked adrenoleukodystrophy (X-ALD) is an inherited demyelinating disorder 
characterized by the accumulation of saturated very long chain fatty acids (VLCFA) in plasma and 
tissues. Adrenocortical insufficiency and symptoms of alopecia and hypogonadism  indicate a role 
of steroid hormones, particularly androgens in this disease. Fibroblasts from X-ALD patients 
exhibit abnormalities in the function and mRNA abundance of 5alpha-reductase, a key enzyme in 
testosterone metabolism.  Lamellar inclusions rich in VLCFA esterified with cholesterol in the 
adrenals and testes contribute to  the malfunctioning of these tissues.  The homeostasis of 
cholesterol, the precursor of steroid hormones, and some related metabolic pathways are also 
perturbed in X-ALD.  
 
INTRODUCTION 
 
X-linked adrenoleukodystrophy (X-ALD, OMIM #300100) is an inherited neurological 
disorder resulting from the accumulation of saturated very long chain fatty acids (VLCFA). 
Although these fatty acids accumulate in plasma and in all tissues, the main functional 
abnormalities in X-ALD concern the nervous system with demyelination, adrenocortical 
insufficiency, and hypogonadism [1,2]. 
 
VLCFA metabolism in X-ALD 
 
The accumulation of VLCFA in plasma and fibroblasts is the biochemical marker of X-
ALD. In particular, elevated plasma levels of hexacosanoic acid (26:0) and tetracosanoic acid (or 
lignoceric acid, 24:0) confirm the diagnosis of X-ALD.  
VLCFA metabolism is modified in both the catabolic and biosynthetic pathways. Under 
physiological conditions, VLCFA are first shortened in the peroxisomes by beta-oxidation 
processes and then further catabolized in the mitochondria.  The beta-oxidation enzymes in 
peroxisomes appear to be normal in X-ALD. Thus, the alteration in VLCFA catabolism is likely 
further upstream, for example, in the import of VLCFA, which requires the transport protein ALDP 
encoded by the gene mutated in X-ALD [3]. 
VLCFA accumulation in X-ALD is also due to alteration of the VLCFA biosynthetic 
pathway. Tsuj et al. demonstrated that the VLCFA elongation process [4,5], which takes place in 
the microsomes, is augmented in X-ALD fibroblasts. The metabolism of other fatty acids can 
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likewise be affected in the disease [6].Other processes such as oxidative stress have a role in the 
disease [7]. 
VLCFA, as well as other fatty acids, can be further esterified with cholesterol. As discussed 
later, the esterification of VLCFA with cholesterol can also present some abnormalities in X-ALD. 
 
The X-ALD gene 
 
X-ALD results from mutations in the ALD (ABCD1) gene (MIM 300371), which encodes a 
peroxisomal protein (ALDP) that exhibits significant homology to subfamily D of the ATP-binding 
cassette (ABC) family of transporters.  The ABCD1 gene is located on the long arm of the X 
chromosome (Xq28) [3,8] spans 21 kb and contains 10 exons. Its encoded protein, ALDP, has 
significant homology to the peroxisomal membrane protein PMP-70. The function of ALDP is 
thought to be related to VLCFA catabolism but the precise role of this protein is unclear [8].  
ALDP is a half-size protein, after integration into the membrane, ALDP must dimerize to 
form a full functional transporter. Whether ALDP forms a homodimer or a heterodimer has not yet 
been determined, although indirect evidence favors homodimerization. The ABCD subfamily is 
composed of four peroxisomal proteins encoded by the ABCD1–ABCD4 genes. Heterodimerization 
of peroxisomal ABC proteins appears to occur, at least for the adrenoleukodystrophy-related protein 
ALDRP (encoded by ABCD2), the 70-kDa peroxisomal membrane protein PMP70 (encoded by 
ABCD3), and the 69-kDa peroxisomal membrane protein PMP69 (encoded by ABCD4) [9,10]. 
 
Mutations 
 
The known mutations in the ABCD1 gene are listed at http://www.x-ald.nl. A variety of 
missense mutations, nonsense mutations, single amino acid deletions, frameshifts, and splice 
acceptor-site defects have been identified, although there is a clustering of mutations in the amino-
terminal half of ALDP including TMD1–6, loop1–5, and the NBD. Sixty percent of all mutations 
are of the missense type [10,11].  
Epidemiological studies have indicated that there is no apparent predilection for any particular 
ethnic group in the manifestation of the various forms of X-ALD, [12] and its estimated incidence is 
1:17,000 in all groups [9,13]. 
 
4 
 
Phenotypes 
 
Clinical manifestations of X-ALD can be divided into two main subgroups: the rapidly 
progressive cerebral form (CCALD), which shows confluent cerebral demyelination and, usually, 
childhood onset and the slowly progressive adrenomyeloneuropathy (AMN) phenotype, 
characterized by axonopathy of the pyramidal and somatosensory tracts and peripheral neuropathy 
later in life. There is no general correlation between the type of ABCD1 gene mutation and the 
clinical phenotype, although polymorphisms related to methionine metabolism can be correlated 
with demyelination [14]. 
The diversity of clinical presentations of X-ALD makes an accurate laboratory diagnosis 
indispensable. As in many genetic diseases, it is important to reliably identify not only affected 
patients but also heterozygous carriers. When X-ALD is suspected, the first diagnostic step consists 
of analysis of VLCFA in plasma. The diagnosis of ALD and AMN is established by measurement 
of the absolute levels of C26:0 as well as by calculation of the C24:0/C22:0 and C26:0/C22:0 ratios. 
C22:0 is used as a standard because its metabolism, and consequently its plasma and tissue levels 
are normal in X-ALD [15]. 
 
Therapy 
 
Lorenzo’s oil represents the most important therapeutic approach available for X-ALD. This 
therapy was developed by the extraordinary efforts of Augusto and Michaela Odone, parents of the 
affected boy Lorenzo.  The contribution of the late Hugo Moser strongly stimulated research into 
Lorenzo’s oil.  
At the beginning of their studies, Rizzo et al. [16] supplemented skin-fibroblasts with oleic 
acid. Subsequently, a mixture of two monounsaturated fatty acids, oleic acid and erucic acid (cis-
13-docosenoic acid, 22:1) was studied. Lorenzo’s oil is composed of a mixture of these two fatty 
acids, administered to patients as glyceryl trioleate and glyceryl trierucate (4:1) [17].  These 
monounsaturated fatty acids compete with saturated fatty acids for the same microsomal elongating 
enzymes, thus decreasing the synthesis of VLCFA [18].  
The combination of dietary restriction and supplementation with Lorenzo’s oil produces 
significant reductions in plasma VLCFA levels and appears to have a preventive effect in 
asymptomatic boys whose brain MRI is normal [12,19]. Due to the lack of a control group in the 
clinical studies performed thus far, it is difficult to evaluate the efficacy of the therapy in the 
progression of the disease. Current therapies for X-ALD include hormonal replacement therapy for 
5 
 
adrenal insufficiency or hypogonadism, which is needed for all patients with impaired adrenal 
function, but does not significantly arrest neurological progression [2]. 
Another therapeutic option is bone marrow transplantation, which has shown to be of long-
term benefit in the inflammatory forms of X-ALD [20].  Other therapeutic approaches are under 
investigation. These include phenylbutyrate, which showed promising results in a mouse model of 
X-ALD, arginine butyrate and lovastatin. Because overexpression of ABCD1’s closest homologue, 
ABCD2, has been shown to partially compensate for ALDP deficiency, there is particular interest in 
developing approaches that increase the expression of ABCD2, and in long-term gene replacement 
therapy [9, 21, 22, 23, 24]. 
 
Androgen And Lipid Metabolism In X-ALD 
 
Although VLCFA accumulate ubiquitously in plasma and tissues of X-ALD patients, 
specific organs such as the nervous system, the adrenal cortex, and the testes, are particularly 
affected. Lamellar inclusions, rich in VLCFA esterified with cholesterol, have been found in the 
adrenals and testes of X-ALD patients [25,26]. The specific involvement of these organs indicates a 
role of steroidogenesis in X-ALD. 
 
Cholesterol esters are key metabolites of  lipid and steroid hormone metabolic pathways 
 
The adrenals are very rich in the esterified form of cholesterol. These esters can be 
considered crucial metabolites in X-ALD metabolic pathways. After hydrolysis, cholesterol and 
VLCFA follow distinct pathways. Due to entrapment of cholesterol in VLCFA esters, cholesterol 
homeostasis is perturbed in X-ALD. This observation is particularly relevant considering that 
cholesterol is the precursor of all steroid hormones. As discussed above, the metabolism of VLCFA 
after its hydrolysis, is impaired in X-ALD.  
In steroidogenic tissues, free cholesterol can be obtained in three ways: after cholesterol 
ester hydrolysis, de novo synthesis from acetate, or mainly imported from lipoproteins by specific 
receptor-mediated pathways [27]. In the adrenals, this mechanism is mediated by 
adrenocorticotropic hormone (ACTH). 
In vitro studies have demonstrated that the membrane microviscosity of cultured human 
adrenocortical cells exposed to VLCFA is altered, decreasing their ability to respond to ACTH [28]. 
In X-ALD patients the ACTH-induced response of the adrenals is decreased. Consequently, the use 
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of cholesterol by lipoproteins is reduced, thus impairing the utilization of cholesterol for steroid 
hormone synthesis.   
The esterification process can be relevant, for X-ALD and other disorders because, steroid 
hormones can utilize similar enzymatic systems as cholesterol and can be esterified with fatty acids 
or VLCFA [29]. 
 
Involvement of lipoproteins in neurodegeneration 
 
The highest content of cholesterol is found in the nervous system, especially in myelin 
membranes, where cholesterol together with sphingomyelin and selected glycolipids (cerebrosides 
and sulphatides) plays a major structural role. 
The impairment of mechanisms, involving lipoproteins and related receptor-mediated 
mechanisms, also plays roles in other neurodegenerative disorders such as Alzheimer’s disease. In 
X-ALD, these deficits may be relevant to the demyelinating processes. Apolipoprotein E (Apo E) is 
the main apolipoprotein in the nervous system, where it plays a central role in cholesterol 
utilization.  
Apo E is present in steroidogenic tissues such as the adrenals and the testes [30], and its high 
expression in adrenocortical cells suggests possible roles in modulating the availability of 
cholesterol for steroidogenesis and in cholesterol ester storage [31]. Androgens can have a positive 
effect on the nervous system similar to the better known effects of estrogens [32]. The interactions 
between androgens and Apo E have been considered always more important [33,34]. 
 
Role of androgens in X-ALD 
 
The synthesis of steroid hormones from cholesterol is a complex process that leads to the 
production of molecules with highly diversified biological activity.  
Some X-ALD symptoms point to a particular role of androgens in this disease.  Alopecia, a 
symptom related to alterations in the testosterone metabolic pathway, can develop in X-ALD 
patients [35,36]. Clinical observations have evidenced cases arising even before the onset of 
puberty. Hypogonadism affects a certain percentage of X-ALD patients and testosterone is used as a 
therapy but its effects on VLCFA accumulation and clinical symptomatology need to be assessed 
[37]. 
A key enzyme in the metabolic route of androgens is 5alpha-reductase (5alpha-R), present in 
isoforms 1 and 2.  Alopecia, affecting a certain percentage of X-ALD patients, is related to 
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androgen perturbation  and to altered activity of 5alpha-R [38]. This enzyme converts testosterone 
into its main metabolite dihydrotestosterone (DHT), which acts on the same androgen receptors and 
is 10 times more powerful than testosterone. 5alpha-R also utilizes other steroid hormones as 
substrates, whose potential roles in X-ALD have never been investigated. 
DHT and its metabolite 5alpha-androstan-3alpha,17beta-diol (3alpha-diol), but not 
testosterone itself, incubated in X-ALD fibroblasts, were able to reduce VLCFA accumulation in a 
certain percentage of cases in an acute in vitro study (6-hour incubation) [39]. The rapid effects of 
steroid hormones on a variety of biologicl parameters are due to their particular mechanism of 
action. The same effect of decreased VLCFA accumulation was observed for 
dehydroepiandrosterone, the main androgen in the adrenals, in a chronic in vitro study [40].  
When we tested the activity of 5alpha-R by using labeled testosterone, its conversion into 
DHT was significantly reduced in all X-ALD cases compared with controls. This metabolic 
conversion is the sum of the activities of both isoforms.  
When we evaluated the mRNA abundance of the distinct isoforms, isoform 2 was 
overexpressed with respect to controls in some X-ALD fibroblasts, whereas isoform 1 was not 
affected [38]. The expression of the proteins for both isoforms was not published  because of the 
low specificity of the human antibodies tested. In X-ALD fibroblasts, 5alph-R might not be 
functioning properly and poor DHT production could be the cause of the enzyme’s overexpression.  
If the activity of 5alpha-R is impaired in X-ALD patients, testosterone given as therapy for 
hypogonadism could exhibit altered conversion into DHT and its metabolites. 
 
CONCLUSION 
 
X-ALD, which arises from mutations in the gene encoding a peroxisomal protein transporter 
(ALDP), is a complex disease whose molecular mechanisms and metabolic pathways have not been 
fully elucidated.  Not only is VLCFA metabolism altered  but cholesterol homeostasis and 
lipoprotein-related mechanisms are also perturbed.  Lipoprotein metabolic pathways need to be 
clarified due to their function in transporting both  lipids and steroid hormones. The role of 
androgens requires further research for a better understanding of the pathogenesis of X-ALD. 
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